Pages

logo

logo

Wednesday, July 22, 2026

22/07/26, 200% Tariff on Indian Generics

 US President Donald Trump has escalated his push to bring pharmaceutical manufacturing back to America, announcing a phased tariff regime that could eventually impose a staggering 200 percent duty on imported generic medicines. For India's $9.7-billion pharmaceutical export engine to the US, the announcement has triggered fresh uncertainty but not immediate alarm.

On July 21, Trump posted on Truth Social that generic drugs entering the US will continue to enjoy zero tariffs for two years starting August 1. The duty will jump to 100 percent in August 2028 and double to 200 percent from August 2029. Trump has tied the tariffs to a broader effort to force manufacturers to set up production facilities in the US.

The official order is not yet out.

Why Trump is pressing ahead

The move is part of a wider pharmaceutical reshoring strategy that Trump has been pursuing through Section 232 investigations, a trade mechanism that allows the US administration to impose restrictions if imports are deemed a national security threat.
The commerce department's Section 232 review concluded that America's heavy dependence on imported medicines and pharmaceutical ingredients poses risks to both healthcare security and national preparedness.

In April, Trump used the Section 232 framework to impose steep tariffs on patented drugs and pharmaceutical ingredients while exempting generic medicines. The proclamation said generic drugs would not be subject to tariffs "at this time" and directed authorities to review the segment within a year. The latest announcement suggests that Washington has now turned its attention to generics market where India is the dominant overseas supplier.

Currently, generic drugs are exempt from tariffs in the US.

Impact on Indian drugmakers

Indian drugmakers account for roughly 40-50 percent of all generic prescriptions dispensed in the US.

There is no immediate earnings hit for India drugmakers. India exports more than $9.7 billion worth of pharmaceuticals to the US annually, with generics forming the backbone of that trade.

The two-year window provides time to evaluate manufacturing investments, restructure supply chains or negotiate potential exemptions. All major Indian drugmakers have manufacturing facilities in US to make formulations and finished dosages.

A key unanswered question is whether tariffs will apply only to finished formulations or also to active pharmaceutical ingredients (APIs), many of which are sourced globally. Industry executives say the final rules will determine the real impact on profitability.

What experts are saying

Thomas V Abraham, research analyst at Mirae Asset Sharekhan, said the market is waiting for greater clarity. According to him, most major Indian companies already have a manufacturing presence in the US, either through acquisitions or organic investments. A two-year runway may be sufficient to comply if local manufacturing requirements become a prerequisite.

Branded drugmakers previously negotiated arrangements with the US government to soften the impact of policy changes, a route that generic companies could potentially explore as well, he said.

Industry body the Indian Pharmaceutical Alliance struck a conciliatory tone. Secretary General Sudarshan Jain said Indian companies operate more than 40 facilities in the US, support local jobs, and contribute to supply-chain resilience. The association said it would continue engaging with the US administration to strengthen healthcare and medicine security for both countries.

Others see the announcement as a strategic wake-up call. Entod Pharmaceuticals CEO Nikkhil Masurkar said Indian pharma has become overly dependent on the US market and should accelerate expansion in the Middle East and other regions in Asia as well as Africa and Latin America. Diversification is an essential rather than an option, he said.

Is it a negotiating tool?

An analyst who didn't want to be named said the announcement may be a negotiating tool to extract a favourable trade deal with India.

"Generic medicines operate on razor-thin margins and manufacturing in the US carries significantly higher costs than India," he said.

Generics account for more than 90 percent of prescriptions dispensed in America, raising concerns that steep tariffs could ultimately increase healthcare costs for US consumers.

Analysts say that doubling the prices of essential medicines in an election year would be a political disaster.

Report by Vishwanath Pillai
Source:moneycontrol

No comments:

Today's

22/07/26, 200% Tariff on Indian Generics

  US President Donald Trump has escalated his push to bring pharmaceutical manufacturing back to America, announcing a phased tariff regime ...